AARD Stock Forecast & Price Target

Aardvark Therapeutics is attractive because its exploratory Phase 3 HERO and open-label extension data point to a real drug effect in PWS patients, with ARD-101 showing a modest HQ-CT improvement versus placebo at week two and a 6-point average HQ-CT reduction in participants who switched from placebo in the OLE. The fact that scores returned near baseline after discontinuation, while placebo had less rebound, strengthens the case that the signal is pharmacologically driven rather than random noise. In addition, ARD-101 was generally well-tolerated with mostly mild to moderate adverse events, supporting a favorable risk-benefit profile for a clinical-stage biopharmaceutical asset targeting a large unmet need in hyperphagia-associated conditions.

Aardvark Therapeutics is facing a fundamentally fragile investment case because its lead asset, ARD-101, has been hampered by a clinical hold, trial termination, and an unclear regulatory path despite initial signs of activity in PWS. The company’s situation is further weakened by safety concerns tied to reversible ECG changes, the need for additional FDA alignment, and the fact that the development timeline for market entry may be materially delayed. With a DCF-based total firm value of $71M to $140M, relatively low probabilities of approval, and explicit medium-term equity dilution risk, the stock’s downside remains anchored in both execution and financing uncertainty.